IMMUPHARMA PLC LS-01
Research IMMUPHARMA PLC LS-01 (25I) on Bullrun: market cap EUR 14.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker25I
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 14.35M
- Financial periodFY2024
- Net income-EUR 2.48M
- Free cash flow-EUR 1.77M
Valuation Snapshot
latest market cap is EUR 14.35M.
About IMMUPHARMA PLC LS-01
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology;
Frequently asked questions
What is IMMUPHARMA PLC LS-01's market cap?
IMMUPHARMA PLC LS-01's market capitalization is EUR 14.35M.
What does IMMUPHARMA PLC LS-01 do?
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally.